A Pyruvate-Buffered Dialysis Fluid Induces Less Peritoneal Angiogenesis and Fibrosis than a Conventional Solution

Heimburger O. , Waniewski J. , Werynski A. , Tranaeus A. , Lindholm B. Peritoneal transport in CAPD patients with permanent loss of ultrafiltration capacity. Kidney Int 1990; 38: 495–506.

Davies S.J. Longitudinal relationships between solute transport and ultrafiltration capacity in peritoneal dialysis patients. Kidney Int 2004; 66: 2437–45.

Krediet R.T. , Lindholm B. , Rippe B. Pathophysiology of peritoneal membrane failure. Perit Dial Int 2000; 20(Suppl 4): S22–42.

Mateijsen M.A.M. , van der Wal A.C. , Hendriks PMEM , Zweers M.M. , Mulder J. , Struijk D.G. Vascular and interstitial changes in the peritoneum of CAPD patients with peritoneal sclerosis. Perit Dial Int 1999; 19: 517–25.

Williams J.D. , Craig K.J. , Topley N. , Von Ruhland C. , Fallen M. , Newman G.R. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002; 13: 470–9.

Plum J. , Hermann S. , Fussholler A. , Schoenicke G. , Donner A. , Rehrborn A. Peritoneal sclerosis in peritoneal dialysis patients related to dialysis settings and peritoneal transport properties. Kidney Int Suppl 2001; 78: S42–7.

Zweers M.M. , Splint L.J. , Krediet R.T. , Struijk D.G. Ultrastructure of basement membranes of peritoneal capillaries in a chronic peritoneal infusion model in the rat. Nephrol Dial Transplant 2001; 16: 651–4.

Inagi R. , Miyata T. , Yamamoto T. , Suzuki D. , Urahani K. , Saito A. Glucose degradation product methylglyoxal enhances the production of vascular endothelial growth factor in peritoneal cells: role in the functional and morphological alterations of peritoneal mesothelial cells in peritoneal dialysis. FEBS Lett 1999; 17: 260–4.

Schlingemann R.O. , van Hinsbergh V.W. Role of vascular permeability factor/vascular endothelial growth factor in eye disease. Br J Ophthalmol 1997; 81: 501–12.

Alvarez-Arroyo M.V. , Caramelo C. , Angeles Castilla M. , Gonzalez Pacheco F.R. , Martin O. , Arias J. Role of vascular endothelial growth factor in the response to vessel injury. Kidney Int Suppl 1998; 68: S7–9.

Tilton R.G. , Kawamura T. , Chang K.C. , Ido Y. , Bjercke R.J. , Stephan C.C. Vascular dysfunction induced by elevated glucose levels in rats is mediated by vascular endothelial growth factor. J Clin Invest 1997; 99: 2192–202.

Williamson J.R. , Osrow E. , Eades D. , Chang K. , Allison W. , Kilo C. Glucose-induced microvascular functional changes in nondiabetic rats are stereospecific and are prevented by an aldose reductase inhibitor. J Clin Invest 1990; 85: 1167–72.

Morrisey K. , Steadman R. , Williams J.D. , Philips A.O. Renal proximal tubular cell fibronectin accumulation in response to glucose is polyol pathway dependent. Kidney Int 1999; 55: 160–7.

Philips A.O. , Morrisey K. , Steadman R. , Williams J. Decreased degradation of collagen and fibronectin following exposure of proximal cells to glucose. Exp Nephrol 1999; 7: 449–62.

Williamson J.R. , Chang K. , Frangos M. , Hasan K.S. , Ido Y. , Kawamura T. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 1993; 42: 801–13.

Zweers M.M. , de Waart D.R. , Smit W. , Struijk D.G. , Krediet R.T. Growth factors VEGF and TGF-beta1 in peritoneal dialysis. J Lab Clin Med 1999; 134: 124–32.

Zweers M.M. , Struijk D.G. , Smit W. , Krediet R.T. Vascular endothelial growth factor in peritoneal dialysis: a longitudinal follow-up. J Lab Clin Med 2001; 137: 125–32.

Krediet R.T. , van Westrhenen R. , Zweers M.M. , Struijk D.G. Clinical advantages of new peritoneal dialysis solutions. Nephrol Dial Transplant 2002; 17(Suppl 3): 16–18.

Kientsch-Engel R.I. , Siess E.A. D-(-)-3-hydroxybutyrate and acetoacetate. In: Bergmeyer H.U. , ed. Methods of Enzymatic Analysis. 3rd ed. Vol. 7. Weinheim: VHC Verlag; 1983: 60–9.

Pannekeet M.M. , Imholz A.L. , Struijk D.G. , Koomen G.C. , Langedijk M.J. , Schouten N. The standard peritoneal permeability analysis: a tool for the assessment of peritoneal permeability characteristics in CAPD patients. Kidney Int 1995; 48: 866–75.

Zweers M.M. , Splint L.J. , Krediet R.T. , Struijk D.G. Effect of fluid supplementation and modality on peritoneal permeability characteristics in a rat peritoneal dialysis model. Perit Dial Int 2001; 21: 58–64.

Koomen G.C.M. , Krediet R.T. , Leegwater A.C.J. , Struijk D.G. , Arisz L. , Hoek F.J. A fast reliable method for the measurement of intra-peritoneal dextran 70, used to calculate lymphatic absorption. Adv Perit Dial 1991; 7: 10–14.

Zemel D. , Imholz A.L.T. , de Waart D.R. , Dinkla C. , Struijk D.G. , Krediet R.T. Appearance of tumor necrosis factor-α and soluble TNF receptors I and II in peritoneal effluent of CAPD. Kidney Int 1994; 46: 1422–30.

Krediet R.T. , Struijk D.G. , Koomen G.C. , Arisz L. Peritoneal fluid kinetics during CAPD measured with intraperitoneal dextran 70. ASAIO Trans 1991; 37: 662–7.

Waniewski J. , Werynski A. , Heimburger O. , Lindholm B. Simple models for description of small-solute transport in peritoneal dialysis. Blood Purif 1991; 9: 129–41.

Zweers M.M. , Imholz A.L. , Struijk D.G. , Krediet R.T. Correction of sodium sieving for diffusion from the circulation. Adv Perit Dial 1999; 15: 65–72.

Westrhenen van R. , de Waart D.R. , Akman S. , Krediet R.T. Assessment of peritoneal fibrosis by conventional light microscopy and hydroxyproline measurement. Perit Dial Int 2004; 24: 290–2.

Hekking L.H. , Zareie M. , Driesprong B.A. , Faict D. , Welten A.G. , de Zeeuw I. Better preservation of peritoneal morphologic features and defense in rats after long-term exposure to a bicarbonate/lactate buffered solution. J Am Soc Nephrol 2001; 12: 2775–86.

Zareie M. , Hekking L.H. , Welten A.G. , Driesprong B.A. , Schadee-Eestermans I.L. , Faict D. Contribution of lactate buffer, glucose and glucose degradation products to peritoneal injury in vivo. Nephrol Dial Transplant 2003; 18: 2629–37.

Mortier S. , Faict D. , Schalkwijk C.G. , Lameire N.H. , De Vriese A.S. Long-term exposure to new peritoneal dialysis solutions: effects on the peritoneal membrane. Kidney Int 2004; 66: 1257–65.

Brunkhorst R. , Mahiout A. Pyruvate neutralizes peritoneal dialysate cytotoxicity: maintained integrity and proliferation of cultured human mesothelial cells. Kidney Int 1995; 48: 177–81.

Shostak A. , Gotloib L. , Kushnier R. , Wajsbrot V. Protective effect of pyruvate upon cultured mesothelial cells exposed to 2mM hydrogen peroxide. Nephron 2000; 84: 362–6.

Ing T.S. , Zhou X.J. , Yu A.W. , Zhou F.Q. , Vaziri N.D. Effects of pyruvate-based or lactate-based peritoneal dialysis solutions on neutrophil intracellular pH. Int J Artif Organs 1997; 20: 255–60.

Wu Y.T. , Wu Z.L. , Jiang X.F. , Li S. , Zhou F.Q. Pyruvate preserves neutrophilic superoxide production in acidic, high glucose-enriched peritoneal dialysis solutions. Artificial Organs 2003; 27: 276–81.

Wy Y.T. , Wu Z.L. , Jiang Y-F , Li S. , Zhou F.Q. Pyruvate improves neutrophilic nitric oxide generation in peritoneal dialysis solutions. Artificial Organs 2005; 29: 976–80.

Mahiout A. , Brunkhorst R. Pyruvate anions in peritoneal dialysate solutions preserve the function of peripheral and peritoneal leukocytes in vitro. Nephrol Dial Transplant 1995; 10: 391–4.

Musi B. , Carlsson O. , Rippe A. , Wieslander A. , Rippe B. Effects of acidity, glucose degradation products, and dialysis fluid buffer choice on peritoneal solute and fluid transport in rats. Perit Dial Int 1998; 18: 303–10.

Albrechtsson A. , Bazargoni F. , Wieslander A. , Braide A. Peritoneal dialysis fluid-induced angiogenesis in rat mesentery is increased by lactate in the presence or absence of glucose. ASAIO J 2006; 52: 276–81.

Zweers M.M. , de Waart D.R. , van der Wal A.C. , Dekker F.W. , Krediet R T. , Struijk D.G. Structural and functional changes of the peritoneum in a chronic peritoneal infusion model in the rat. In: Zweers M.M. , ed. Experimental and Clinical Studies on Peritoneal Physiology and Morphology During Chronic Peritoneal Dialysis [Thesis]. University of Amsterdam; 2000: 77–96.

Imholz A.L.T. , Koomen G.C.M. , Struijk D.G. , Arisz L. , Krediet R.T. Effect of dialysate osmolarity on the transport of low-molecular weight solutes and proteins during CAPD. Kidney Int 1993; 43: 1339–46.

Numata M. , Nakayama M. , Nimura S. , Kawakami M. , Lindholm B. , Kawaguchi Y. Association between an increased peritoneal surface area of peritoneal microvessels and a high peritoneal solute transport rate. Perit Dial Int 2003; 23: 116–22.

Pietrzak I. , Hirszel P. , Shostak A. , Welch P.G. , Lee R.E. , Maher J.F. Splanchnic volume, not flow rate determines peritoneal permeability. ASAIO Trans 1989; 35: 583–7.

Wong T.Y. , Philips A.O. , Witowski J. , Topley N. Glucose-mediated induction of TGFbeta1 and MRCP 1 in mesothelial cells in vitro is osmolality and polyol pathway dependent. Kidney Int 2003; 63: 1404–16.

Linden T. , Cohen A. , Deppisch R. , Kjellstrand P. , Wieslander A. 3,4-dideoxyglucosone-3-ene (3,4-DGE): a cytotoxic glucose degradation product in fluids for peritoneal dialysis. Kidney Int 2002; 62: 697–703.

Witowski J. , Korybalska K. , Wisniewska J. , Breborowicz A. , Gahl G.M. , Frei U. Effect of glucose degradation products on human peritoneal mesothelial cell function. J Am Soc Nephrol 2000; 11: 729–39.

Honda K. , Nitta K. , Horitas S. , Yumura W. , Nihei H. , Nagai R. Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultrafiltration. Nephrol Dial Transplant 1999; 14: 1541–9.

Miayata T. , Horie K. , Keda Y. , Fujita Y. , Izuhara Y. , Hirano H. Advanced glycation and lipidoxidation of the peritoneal membrane: respective roles of serum and peritoneal fluid reactive carbonyl compounds. Kidney Int 2000; 58: 425–35.

Devuyst O. , van Ypersele de Strihou C. Nitric oxide, advanced glycation end products, and uremia. Kidney Int 2000; 4: 1814–15.

Van Erven D.M.M. , Gabreëls F.J.M. , Wevers R.A. , Doesburg W.H. , Ruitenbeek W. , Renier W.O. Intravenous pyruvate loading test in Leigh syndrome. J Neurol Sci 1987; 77: 217–27.

Kristo G. , Yoshimura Y. , Niu J. , Keith B.J. , Mentzer R.M. Jr. , Lasley R.D. The intermediary metabolite pyruvate attenuates stunning and reduces infarct size in vivo porcine myocardium. Am J Physiol Heart Circ Physiol 2004; 286: H517–H524.

Hermann H.P. , Arp J. , Pieske B. , Kogler H. , Baron S. , Janssen P.M.L. Improved systolic and diastolic myocardial function with intracoronary pyruvate in patients with congestive heart failure. Eur J Heart Fail 2004; 6: 213–18.

Olivencia-Yurvati A.H. , Blair J.L. , Baig M. , Mallet R.T. Pyruvate-enhanced cardioprotection during surgery with cardiopulmonary bypass. J Cardiothorac Vasc Anesth 2003; 17: 715–20.

Mallet R.T. , Sun J. , Knott M.E. , Sharma A.B. , Olivencia-Yurvati A.H. Metabolic cardioprotection by pyruvate: recent progress. Exp Biol Med 2005; 230: 435–43.